French Pharma Stock News

Why TotalEnergies stock is drawing attention now TotalEnergies (ENXTPA:TTE) is back on many investors’ screens after recent share price moves, with the stock showing positive returns over the past week, month and past 3 months. See our latest analysis for TotalEnergies. The recent 7 day share price return of 3.1% and 90 day share price return of 7.8% suggest positive momentum, while the 1 year total shareholder return of 5.0% and 5 year total shareholder return of 111.7% point to solid longer...

Voltalia (ENXTPA:VLTSA) has drawn fresh attention after guiding that its net loss attributable to the Group in the second half of 2025 will be higher than in the first half, sharpening investor focus on profitability. See our latest analysis for Voltalia. At a share price of €7.32, Voltalia has seen a 4.2% 1 month share price return, while the 1 year total shareholder return of 8.9% contrasts with a much weaker 3 and 5 year total shareholder return, suggesting recent momentum is tentative...

OVH Groupe (ENXTPA:OVH) has drawn fresh attention after reporting first quarter fiscal 2026 revenue of €275.3 million, compared with €263.5 million a year earlier, giving investors new data to reassess the stock. See our latest analysis for OVH Groupe. The revenue update appears to have coincided with a sharp shift in sentiment, with a 22.68% 1 month share price return partly offsetting a 26.27% 3 month share price decline and a 45% 3 year total shareholder return loss. If OVH Groupe’s latest...

Getlink (ENXTPA:GET) has put fresh operating data on the table, with December and full year 2025 traffic figures showing softer freight volumes alongside slightly higher annual passenger vehicle numbers for its LeShuttle services. See our latest analysis for Getlink. At a share price of €16.18, Getlink has seen a 5.27% 1 month share price return and a 3.65% 3 month share price return. The 1 year total shareholder return of 8.99% and 5 year total shareholder return of 38.83% suggest momentum...

Most readers would already be aware that OPmobility's (EPA:OPM) stock increased significantly by 13% over the past...

In January 2026, Exosens announced its largest-ever order from ACTinBlack Group for more than 7,000 5G image intensifier tubes, to be delivered in 2027–2028 for integration into night-vision goggles used by undisclosed European Special Forces. This contract underscores the growing adoption of Exosens’ highest-performance night-vision technology and reinforces its role as NATO’s key supplier for advanced defense imaging systems. We’ll now examine how this record 5G image intensifier order,...

If you are looking at Danone and wondering whether the current share price really lines up with the underlying business, this article is designed to walk you through that question in a clear, practical way. Danone shares most recently closed at €75.44, with returns of a 1.8% decline over 7 days, a 3.6% decline over 30 days, a 0.8% decline year to date and a 19.4% gain over 1 year, 65.2% over 3 years and 63.3% over 5 years, which gives useful context before thinking about what the stock might...

In early January 2026, Veolia Environnement completed a record €2.50 billion multi-tranche bond issuance in reopened European markets, including 5-, 8- and 12-year bonds with fixed coupons between 3.209% and 4.052%, following very strong investor demand of €10.50 billion and slight negative to low-single-digit basis point new issue concessions. The high level of oversubscription, tight pricing versus secondary markets, and the AMF-compliant liquidity contract update collectively highlight...

In January 2026, Dassault Aviation société anonyme raised its 2025 net sales guidance to over €7 billion, signaling stronger anticipated revenue than previously communicated. This upward revision highlights management’s increased confidence in the company’s order visibility and demand outlook across its defense and business aviation programs. We’ll now explore how this higher 2025 sales guidance could influence Dassault Aviation’s existing investment narrative and expectations for future...

In late 2025, data from the UK used-car market showed that popular secondhand electric vehicles lost significant value, with the Renault Zoe among the models experiencing some of the sharpest price declines as manufacturers cut prices on new EVs to meet regulatory sales targets. This rapid drop in used EV prices raises questions about residual values and consumer confidence in Renault’s electric line-up at a time when the group is investing heavily in its transition to battery-powered...

Why Thales Stock Is Back in Focus After CES 2026 Thales (ENXTPA:HO) is back on investors’ radar after CES 2026 recognition for a Samsung security chip that embeds Thales’ post quantum ready operating system and cryptographic libraries to protect connected devices. See our latest analysis for Thales. Thales’ €261.6 share price sits on the back of a 15% 1 month share price return and 11% year to date share price return, while its 1 year total shareholder return of about 79% points to strong...

Vinci (ENXTPA:DG) is back in focus after a consortium led by its construction arm secured a contract worth more than €200 million to overhaul the Romainville Bobigny household waste treatment plant near Paris. See our latest analysis for Vinci. At a share price of €117.45, Vinci’s short term share price returns have been slightly negative in recent weeks, but the 1 year total shareholder return of 19.18% and 5 year total shareholder return of 75.16% point to a stronger longer term picture...

Orange has in early January 2026 successfully priced a US$6.00 billion multi-tranche US dollar bond issue, spanning maturities from 2029 to 2056 with fixed coupons between 4.00% and 5.75%, to fund general corporate purposes including refinancing debt linked to its planned full acquisition of MasOrange. The more than very large oversubscription and the issuer’s first US dollar deal since 2016 highlight both strong credit-market appetite for Orange paper and a deliberate move to broaden its...

If you are wondering whether Sanofi’s current share price lines up with its underlying worth, you are not alone. This article is here to unpack that question clearly. Sanofi’s share price closed at €80.78, with returns of a 4.3% decline over 7 days, 1.6% decline over 30 days, 1.9% decline year to date, 14.1% decline over 1 year, 0.4% gain over 3 years and 20.8% gain over 5 years, which may have some investors reassessing the balance between risk and opportunity. Recent news coverage around...

The Teract S.A. ( EPA:TRACT ) share price has done very well over the last month, posting an excellent gain of 108...

Omer-Decugis & Cie SA ( EPA:ALODC ) shareholders have had their patience rewarded with a 27% share price jump in the...

Ideally, your overall portfolio should beat the market average. But in any portfolio, there will be mixed results...

Why Société Générale Société anonyme (ENXTPA:GLE) Is On Investors’ Radar Société Générale Société anonyme (ENXTPA:GLE) has been drawing attention after a strong past 3 months total return of about 31%. This has prompted investors to reassess how its current share price compares with underlying fundamentals. See our latest analysis for Société Générale Société anonyme. That recent 31.1% 90 day share price return, alongside a very large 1 year total shareholder return of about 153%, suggests...

Recent share performance and business profile Kering (ENXTPA:KER) has seen its share price decline over the past week and month, while still showing a positive total return over the past year. Its performance has been weaker when you look at the past 3 years and 5 years. The group reported annual revenue of €15,763.0m and net income of €729.0m. Revenue and net income growth data are available for investors who want to compare its recent results with other luxury names. See our latest analysis...

74Software stock snapshot after recent price moves 74Software (ENXTPA:74SW) has been on investors’ radar after a recent pullback, with the share price sitting at €38.40 and short term returns over the past week and month both in decline. See our latest analysis for 74Software. While the recent 1 week and 1 month share price returns are in decline, the 90 day share price return of 4.35% and 1 year total shareholder return of 41.7% point to momentum that has eased but not reversed. If...

A consortium of market infrastructure and trading firms recently completed a third wave of transactions on the Canton Network, using tokenized commercial bank deposits via LSEG Digital Settlement House and tokenized collateral such as European government bonds and U.S. Treasuries for on-chain intraday repo across multiple currencies and borders. Euronext highlighted that this work is part of a broader industry push to build tokenization and on-chain infrastructure while staying aligned with...

Ayvens issues new fixed income notes Ayvens (ENXTPA:AYV) has launched a fixed income offering of €750 million in 3.0% non convertible notes due April 18, 2030, a funding move that can matter for both equity and bond investors. See our latest analysis for Ayvens. The bond issue comes as Ayvens’ share price sits at €11.86, with a 30 day share price return of 9.92% and a 1 year total shareholder return of 85.34%, suggesting momentum has recently been building from a relatively strong base. If...

Veolia Environnement (ENXTPA:VIE) is back in focus after completing a record €2.5b bond placement across three new tranches, issued on terms that drew strong oversubscription and highlighted robust investor appetite. See our latest analysis for Veolia Environnement. While the new €2.5b bond placement has reinforced confidence among credit investors, the equity story looks more measured. The share price is at €29.84 with a modest 1.1% 1 month share price return, alongside a stronger 1 year...

If you are wondering whether ABIVAX Société Anonyme is priced attractively right now, it helps to separate the recent excitement from what the numbers actually say about value. The share price last closed at €103.60, with returns of 4.4% over 7 days, 10.1% over 30 days and a very large gain over the past year, although year to date the stock shows a 9.9% decline. These moves have come as ABIVAX Société Anonyme continues to attract attention in the French pharmaceuticals and biotech space,...